Is Mycobacterium tuberculosis infection life long?

People with immunoreactivity to tuberculosis are thought to have lifelong asymptomatic infection and remain at risk for active tuberculosis. Marcel A Behr and colleagues argue that most of these people are no longer infected.

Marcel A Behr professor of medicine, Paul H Edelstein professor of pathology and laboratory medicine, Lalita Ramakrishnan professor of immunology and infectious diseases

1Department of Medicine, McGill University, McGill International TB Centre, Montreal, H4A 3J1, Canada; 2Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA; 3Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK

Key messages
- Two billion people worldwide are thought to be asymptptomatically (latently) infected with Mycobacterium tuberculosis and at risk of developing active tuberculosis (TB)
- The prevalence of latent TB infection is inferred from tests that detect immunoreactivity to mycobacterial antigens rather than live bacteria and from mathematical modelling
- Longitudinal studies and clinical trials show that this TB immunoreactivity can persist after curative treatment
- Most people with TB immunoreactivity do not develop active TB upon immunosuppression, suggesting that they have cleared their infection while retaining immunological memory to it
- TB immunoreactivity cannot distinguish cleared from persistent infection, emphasising the urgent need for tests that can identify people with asymptomatic infections

A critical component of the World Health Organization’s End TB strategy is the prevention of active tuberculosis (TB) by treating people with latent TB infection.1,2 This requires knowledge of who is latently or asymptptomatically infected with Mycobacterium tuberculosis. As there are no direct tests for asymptomatic infection, it is inferred from the presence of TB immunoreactivity, determined by either a tuberculin skin test (TST) or an interferon gamma release assay (IGRA). The use of immunoreactivity as a proxy for infection is based on the assumption that those testing positive harbour live bacteria, which might be quiescent now but can spring to activity to cause disease later, especially if the host becomes immunocompromised.2,1

Is this assumption valid? Knowing this would be useful for several interested parties—public health officials, TB researchers, people showing TB immunoreactivity, and doctors. We tested the assumption that TB immunoreactivity equals persistent infection by analysing the natural history of TB immunoreactivity in people given preventive treatment and of active TB in immunoreactive people with various forms of severe immunosuppression.

**Immunoreactivity does not reflect continued infection**

For TB immunoreactivity to be a reliable proxy for persistent TB infection, it must track faithfully with infection. This means that people whose infection is cured should become non-reactive. Multiple studies show that this is not the case. The large US isoniazid chemoprophylaxis trial conducted between 1956 and 1966 showed that treatment of people with TB immunoreactivity (TST results ≥10 mm) for one year lowered the incidence of active TB by 60-70% over the next nine years (fig 1A).1 Yet the treated people remained positive on TST up to nine years after treatment (fig 1B), showing that TB immunoreactivity can outlast elimination of infection by at least nine years.

This finding was validated by two studies that provided mechanistic insights. Among hospital employees, Atuk and Hunt showed that patients who had positive results on TSTs for more than a year before treatment remained so after treatment, whereas 50% of those who had been positive for less than a year became negative or had smaller TST induration size (fig 1C).2 Houk and colleagues’ study of US navy sailors treated with isoniazid for TB infection provided more granularity.3 All who were immunoreactive for more than a year before treatment remained so after treatment; among the remainder, those who were immunoreactive the longest were most likely to remain so after isoniazid treatment (fig 1D). These findings are consistent with the development of a lasting immunological memory that becomes more robust with longer exposure to antigen. Finally, the finding that TB immunoreactivity outlasts
immunosuppression used. Some of the later cases might have been from newly acquired infection after the transplant, in which case the estimated risk attributable to remote infection would be even lower.

**Haematopoietic stem cell transplantation**

Haematopoietic stem cell transplantation results in the most profound and rapid immunosuppression affecting both innate and adaptive arms of immunity; this is the most likely form of immunosuppression to cause any quiescent *M. tuberculosis* to become active. We identified four cohorts of TB immunoreactive people in India, South Korea, Taiwan, and the US who underwent haematopoietic stem cell transplantation without receiving isoniazid prophylaxis. The proportion of these cohorts that developed TB was less than 10% (fig 4A). In the US cohort, none of 29 participants with TB immunoreactivity developed TB after a total of 89 person years of observation. The three other studies were performed in countries with intermediate to high TB burden, yet only 7-10% of people developed TB. The median times to TB development after transplantation were 258, 368, and 445 days for the Indian, South Korean, and Taiwanese studies (fig 4B), respectively, indicating that some of these cases might have been due to new infection rather than activation of their remote infection.

**BCG and false positives**

BCG vaccination can result in false positive results on TSTs in those vaccinated when older than 1 year of age. This could have falsely inflated the number of people estimated to be TB immunoreactive in the studies that we analysed. If so, the proportion of TB immunoreactive people who developed TB associated with immunosuppression would have been higher than our estimates. To ensure that this was not the case, for each study we determined the use of BCG vaccine in the appropriate country and whether the more specific IGRA tests were used to determine TB immunoreactivity. We concluded that our estimates of TB immunoreactivity were not falsly high because of BCG vaccination (see supplementary table 2).

**Summary and implications**

Whether infected people can clear *M. tuberculosis* has consumed TB researchers for over a century, yet multiple approaches have failed to yield a definitive answer. Our analysis of epidemiological experiments suggests the answer: between 1% and 11% of people with TB immunoreactivity continue to harbour viable bacteria capable of causing disease. In the remainder, the organisms are either dead or have lost their pathogenic potential. The latter scenario would be extraordinary. It would differ from a multitude of other quiescent infections where immunosuppression is recognised to cause a reactivation or exacerbation of infection. *Cyto megalovirus*, herpes simplex virus, herpes zoster virus, the protozoan *Toxoplasma gondii*, and the fungus *Cryptococcus neoformans* are known to produce full blown devastating infections from a long term latent infection.

This analysis highlights that the currently available tests for latent TB infection detect only TB reactivity—that is, immunological memory and recall responses. So they would not be expected to distinguish between long lived memory that persists after elimination of *M. tuberculosis* antigens and T cell responses maintained by repeated antigen stimulation from chronic infection. Many infectious diseases (including hepatitis A, B, and C) as well as immunisation with attenuated or subunit
vaccines generate memory responses (antibody, T cell, or both) that do not reflect pathogen persistence. We hope that our analysis will stimulate further discussion about the research and biological paradigms of TB. If infection is forever, researchers will aim to study host tolerance. If infection can be cleared, researchers will try to understand the mechanisms of pathogen elimination.

Our findings indicate that the tests used in biomarker and immunological studies of persistent infection (TST and IGRA) might have two major confounders: the control participants who do not develop TB might be a heterogeneous mix of currently and previously infected people; and efforts to find a profile that predicts increased risk of disease might be confounded by the control group (TST positive) being at reduced risk of TB, as has been shown in multiple observational studies. Notwithstanding the challenges of evaluating new biomarkers, the importance of identifying the proportion of people with persistent infection and distinguishing them from those with immunological memory of past infection cannot be overstated. A test that could identify the 10% who are infected should reduce the cost and morbidity of treatment 10-fold while maintaining the effectiveness of the intervention. Until we have such a test, our analysis does not affect clinical guidelines for reducing the cost and morbidity of treatment 10-fold while maintaining the effectiveness of the intervention. If people are capable of clearing infection, then estimates of the global prevalence of infection, which are based on the cumulative incidence of new infection, might be underestimated.

Finally, if 90% of people with TB immuno-reactivity do not develop active TB when challenged with TNF neutralising antibodies, HIV, anti-rejection drugs or haematopoietic stem cell transplants, we might be able to reduce the cost and morbidity of treatment 10-fold while maintaining the effectiveness of the intervention. Until we have such a test, our analysis does not affect clinical guidelines for reducing the cost and morbidity of treatment 10-fold while maintaining the effectiveness of the intervention.

Contributors and sources: The contributors are clinician-scientists with a longstanding interest in the pathogenesis and epidemiology of TB. MAB is an expert in bacterial genomics and molecular epidemiology of TB. PHE is an expert in clinical microbiology and infectious diseases. LR is an expert in the immunopathogenesis of mycobacterial infections. All authors searched the literature. PHE performed the calculations for the absolute risk of TB in the various cohorts and MB checked the calculations. All authors wrote the paper and designed the figures; PHE prepared the figures. The sources of information used include a contemporary literature search using PubMed and Google Scholar, including searching systematic reviews, a search of older articles from the pre-antibiotic era. PHE is the guarantor.

Funding: This work was funded by a foundation grant from the Canadian Institutes for Health Research (MAB), and the Welcome Trust, the National Institute of Health Research Cambridge Biomedical Research Centre, and the National Institutes of Health (LR). The authors’ funders had no influence on this article. Competing interests: We have read and understood BMJ policy on conflicts of interests and have none to declare.
Figures

**Fig 1** TB immunoreactivity reversion over time. A) Efficacy of one year of isoniazid prophylaxis (n=9382) versus placebo (n=9140) over a 10 year observation period, including the year of treatment, for residents of US mental institutions. Isoniazid treatment reduced TB disease by 62% over the observation period. B) TB immunoreactivity over a 10 year observation period for residents of Milledgeville mental institution participating in a placebo controlled (n=697) trial of isoniazid treatment (n=686) to prevent TB infection, all of whom were TB immunoreactive at enrolment. C) TB immunoreactivity for University of Virginia Hospital workers with known duration of TST positivity (<1 year (n=20) and >1 year (n=17)) before isoniazid treatment for one year. D) TB immunoreactivity for US navy sailors with known duration of TST positivity (1.5-3 months (n=45), 6 months (n=98), 12 months (n=36), and >12 months (n=24)) before isoniazid treatment for one year. TST=tuberculin skin test.
Fig 2 Percentage of likely or known TB immunoreactive patients who developed TB after infliximab treatment and the kinetics of TB development in these patients. A) Percentage of patients receiving infliximab who were free of TB after infliximab treatment, where columns A, B, C, and D are based on data from Gomez-Reino et al (n=1578), Baldin et al (n=1154), Keane et al (n=2931), and Wolfe et al (n=6460). B) The cumulative frequency of TB development in infliximab treated patients versus the time to develop TB after starting infliximab (n=76) from Keane et al, Gomez-Reino et al, and Wolfe et al. The median, average, and 75th centile time to develop TB after initiation of infliximab were 3, 4.5, and 5.6 months, respectively. Error bars indicate 95% confidence intervals.
Fig 3 Percentage of patients with likely or known TB immunoreactivity who did not develop TB with immunosuppression caused by HIV/AIDS or solid organ transplantation. A) Patients with HIV/AIDS. Data from Moss et al (A) (n=35) and Horsburgh et al (B) (n=106), which used molecular methods to distinguish disease probably due to remote versus new infection. Only disease due to remote TB infection is shown, in those who had not received full courses of isoniazid preventive therapy. The observation periods were 2-5 years. B) After solid organ transplantation. Columns A, B, and C show data from Atasever et al (n=443), Klote et al (n=15 870), and Torre-Cisneros et al (n=4388). C) Kinetics of TB development after solid organ transplantation (n=21). The median, mean, and 75th centile times were 6.0, 5.8, and 8.0 months after transplant, respectively. D) kinetics of TB development after renal transplantation (n=66). The median, mean, and 75th centile times were 12.0, 13.6 and 21 months after transplant, respectively. Error bars indicate 95% confidence intervals.
Fig 4 TB in patients undergoing haematopoietic stem cell transplantation. A) Proportion of people with likely TB reactivity who did not develop TB after haematopoietic stem cell transplantation. Columns A, B, C, and D data are taken from Fan et al (n=240), Cheng et al (n=29), Lee et al (n=550), and Agarwal et al (n=175), respectively. B) kinetics of TB development in 39 patients who developed TB over the 10 year observation period. The median, average, and 75th centile incubation times are 1.6, 1.8, and 2.4 years, respectively. Redrawn from Fan et al. Error bars indicate 95% confidence intervals.